An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
The plan is to advance innovative therapies to drug-resistant cancers
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Nocria’s hand-held device uses gentle, controlled puffs of air in the ears for treating migraine attacks
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
Subscribe To Our Newsletter & Stay Updated
